(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Lloyds Banking Group reports a sharp rise in third-quarter profit, while Shell more than doubles its earnings and announces a USD5 billion share buyback. Premier Inn owner Whitbread expects to benefit from UK budget measures limiting business rates increases for hospitality businesses. Read More
(Alliance News) - AstraZeneca PLC on Saturday and Sunday reported a series of positive clinical trial results for ongoing clinical trials at the European Society for Medical Oncology Congress 2026 in Madrid. Read More
(Alliance News) - Computacenter raises its full-year profit outlook after strong third-quarter trading, while Plus500 forecast annual revenue and earnings ahead of market expectations. GSK has reported positive clinical trial results for two cancer treatments. Read More
(Alliance News) - GSK PLC on Wednesday announced US regulatory approval for its chronic hepatitis B treatment Hibsago, while Hutchmed China Ltd confirmed the completion of a separate licensing agreement with GSK worth up to USD1.30 billion. Read More
(Alliance News) - Fresnillo says it has maintained its annual production forecast, GSK has landed a US drug approval and Quilter reports its net inflows for the year have already topped 2025's level. Meanwhile, drilling at a North Sea gas field co-owned by Shell has been approved. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said AstraZeneca PLC submitted a new drug application to the US Food & Drug Administration for Orpathys, or savolitinib, in combination with Tagrisso for patients with non-small cell lung cancer. Read More
(Alliance News) - Stock prices in London opened higher on Tuesday, as pharmaceutical and mining stocks advanced, while oil prices eased amid signs of progress towards renewed talks between the US and Iran. Read More
(Alliance News) - AstraZeneca submits a US regulatory application for a lung cancer treatment developed with Hutchmed. Close Brothers reports a narrowed annual loss but withholds its dividend amid motor finance uncertainty, while Zigup raises its annual profit expectations after a strong start to the year. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Initiates the phase Ia portion, or initial dose-finding stage, of a global clinical trial of HMPL-A830 in patients with advanced or metastatic solid tumours. Says the first patient received an initial dose in China on September 24. The phase I study will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with the initial dose-escalation stage intended to determine the maximum tolerated dose and recommended dose for expansion. Hutchmed says the antibody-targeted therapy combines a KRAS inhibitor with an anti-EGFR antibody to target KRAS-altered, EGFR-expressing tumours. The company is responsible for global phase I development under an agreement with GSK, which holds worldwide rights outside mainland China, Hong Kong, Macau and Taiwan. Read More
(Alliance News) - Land Securities agrees to sell a London office for GBP211 million, while Entain maintains its annual guidance despite an online betting ban in Brazil. HICL Infrastructure invests around GBP68 million in Scandinavian rail freight operator Hector Rail. Read More
(Alliance News) - Stock prices in London were higher at midday on Thursday, as gains for telecom stocks helped the FTSE 100 edge into positive territory, while investors digested stronger UK services activity and rising inflationary pressures in Europe. Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More
(Alliance News) - Hutchmed China PLC on Thursday announced that its subsidiary, Hutchmed Ltd, has entered into an exclusive development licence agreement with a subsidiary of GSK PLC. Read More
(Alliance News) - M&G swings to a first-half pretax loss attributable to equity holders as short-term investment fluctuations weigh on statutory results, while LondonMetric Property announces GBP105 million of investment activity. Elsewhere, Jet2 says trading remains strong and announces plans to move from AIM to London's Main Market. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Announces "positive high-level results" from the Sanovo China phase 3 trial of Orpathys plus Tagrisso in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer, whose tumours harbour epidermal growth factor receptor mutation and MET overexpression. Orpathys, or savolitinib, combined with Tagrisso or osimertinib, showed "a statistically significant and highly clinically meaningful improvement in progression-free survival" in the high MET and intention-to-treat patient populations, compared with Tagrisso alone. Hutchmed adds that "the combination also demonstrated a very encouraging clinical benefit in [the secondary endpoint of] overall survival" in both populations. Hutchmed is jointly developing Orpathys with AstraZeneca, which is also commercialising the treatment. Read More
(Alliance News) - UK house price growth remains subdued in August despite a modest monthly recovery. Bunzl upgrades its full-year outlook and announces a GBP500 million share buyback, while Bodycote and Gamma Communications accept takeover offers. Read More
(Alliance News) - Hutchmed China Ltd on Friday announced regulatory approval for fanregratinib in China for the treatment of intrahepatic cholangiocarcinoma, a rare cancer that develops in the bile ducts. Read More
(Alliance News) - Goodwin hails record annual profit as a process to sell a unit progresses, Morgan Advanced Materials has exited an investee, netting over GBP50 million, while McBride has secured a deal with a former Reckitt unit. Read More
(Alliance News) - AstraZeneca PLC on Monday announced it is discontinuing the eVOLVE-Lung02 phase III trial after an independent review found its experimental drug volrustomig was unlikely to improve outcomes against the comparator treatment. Read More